假病毒技术用于抗HIV-1药物筛选及抗药性分析

中国生物工程杂志

2010, Vol. 30

Issue (03): 95-99

综述

假病毒技术用于抗HIV-1药物筛选及抗药性分析

谢桂煌¹,赵声兰²,陈朝银^1**

1.昆明理工大学/清华大学生物资源开发工程研究所昆明 650224
2.云南中医学院昆明 650200

Application of Pseudovirus Systems on Anti-HIV-1 Drugs Screening and Drug-resistance Analyzing of HIV-1-Variants

1.Institute of Bioresource R&D of Kunming University of Science and TechnologyTsinghua University, Kunming 650224,China
2.Yunnan University of Traditional Chinese Medicine, Kunming 650200,China

全文: PDF(417 KB) HTML

摘要：

HIV抗药性的产生严重阻碍了HIV疾病的治疗进程，因此开发新的抗HIV药物以及对病毒进行抗药性分析对于提高HIV疾病的治疗效果非常重要。将利用HIV假病毒构建的抗HIV药物评价系统及病毒抗药性分析系统应用于药物筛选及耐药性分析具有常规方法无法替代的优点。介绍了目前常用的几种类型HIV假病毒的特点和构建方法，同时介绍了假病毒感染细胞的系统及其在细胞水平筛选抗HIV药物和对HIV临床分离株进行耐药性分析这两方面的应用，并通过与常规方法进行比较来分析利用假病毒技术进行研究的优势及局限性，还通过总结大量学者的研究成果证明了利用假病毒技术进行药物筛选和抗药性分析具有准确、安全和高效的特点。

关键词： HIV; 假病毒; 药物筛选; 抗药性分析

Abstract:

The emergence of drug-resistant variants during antiretroviral therapy is a serious obstacle to sustained suppression of the human immunodeficiency virus type 1 (HIV-1). For that reason, continued drug discovery and resistance assays are essential for the treatment of HIV-1 infection. Using pseudovirus systems is a more attractive option for the screening of anti-HIV-1 drugs and the analysing of drug resistance. The construction and characterization of the pseudotyped HIV with a single-round infectivity and some novel cell-based pharmacological models for anti-HIV-1 compounds screening and drug-resistance analyzing by using pseudovirus systems were introduced. Meanwhile, a large number of studies have been summarized to prove that using these systems is accurate, safe and efficient.

Key words: HIV Pseudovirus Drug screening Drug resistance analysis

收稿日期: 2009-11-16 出版日期: 2010-03-25

基金资助:

云南省科学研究基金项目 (2006C0046M；07Z10197)、国家自然科学基金（30760304)资助项目

通讯作者: 陈朝银 E-mail: chaoyinchen@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谢桂煌
	赵声兰
	陈朝银

引用本文:

谢桂煌赵声兰陈朝银. 假病毒技术用于抗HIV-1药物筛选及抗药性分析[J]. 中国生物工程杂志, 2010, 30(03): 95-99.

XIE Gui-Huang, DIAO Qing-Lan, CHEN Chao-Yin. Application of Pseudovirus Systems on Anti-HIV-1 Drugs Screening and Drug-resistance Analyzing of HIV-1-Variants. China Biotechnology, 2010, 30(03): 95-99.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/ 或 https://manu60.magtech.com.cn/biotech/CN/Y2010/V30/I03/95

［1］ Briggs J A, Wilk T, Fuller S D. Do lipid rafts mediate virus assembly and pseudotyping. J Gen Virol, 2003, 84(pt4): 757768.
［2］ Sanders D A. No false start for novel pseudotyped vectors. Curr Opin Biotechnol, 2002, 13(5): 437442.
［3］ Cohen J. Did Merck’s failed HIV vaccine cause harm? . Science, 2007, 318(5853): 10481049.
［4］ Cohen J. Promising AIDS vaccine’s failure leaves field reeling. Science, 2007, 318(5847): 2829.
［5］ Heyndrickx L, Vermoesen T, Vereecken K, et al. Antiviral compounds show enhanced activity in HIV1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods, 2008, 148(12): 166173.
［6］种辉辉, 许四宏, 王佑春. 评价HIV1抗病毒药物的重组假病毒法的建立及其初步应用. 药物分析杂志, 2008, 28(6):924927. Zhong H H, Xu S H, Wang Y C.Chin J Pharm Anal, 2008, 28(6): 924927.
［7］ Adelson M E, Pacchia A L, Kaul M, et al. Toward the development of a viruscellbased assay for the discovery of novel compounds against human immunodeficiency virus type 1 . Antimicrob Agents Chemother, 2003, 47(2): 501508.
［8］ Garcia J M, Gao A, He P L, et al. Highthroughput screening using pseudotyped lentiviral particles: A strategy for the identification of HIV1 inhibitors in a cellbased assay. Antiviral Res, 2009, 81(3): 239247.
［9］ Wei X, Decker J M, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T20) monotherapy. Antimicrob Agents Chemother, 2002. 46(6): 18961905.
［10］ Wei X, Decker J M, Wang S, et al. Antibody neutralization and escape by HIV1. Nature, 2003, 422(6929): 307312.
［11］ He J, Choe S, Walker R, et a1. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol, 1995, 69(11): 67056711.
［12］仇超, 彭虹,黄相刚等. 携带绿色荧光蛋白基因的单轮感染活性HIV假病毒的建立及其活性检测. 中华微生物学和免疫学杂志. 2006, 26(5): 394398. Qiu C, Peng H, Huang X G, et al.Chin J Microbiol Immunol, 2006, 26(5): 394398.
［13］曹颖莉, 郭颖. 应用假病毒技术研究HIV1复制抑制剂. 药学学报, 2008, 43(3): 253258. Cao Y L, Guo Y.Acta Pharm Aceutica Sinica, 2008, 43(3): 253258.
［14］ Mastromarino P, Conti C, Goldoni P, et al. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol, 1987, 68(pt9): 23592369.
［15］ Petropoulos C J, Parkin N T, Limoli K L, et a1. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2000, 44(4): 920928.
［16］ Chan E, HeilekSnyder G, Cammack N, et al. Development of a Moloney murine leukemia virusbased pseudotype antiHIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors. J Biomol Screen, 2006, 11(6): 652663.
［17］ Lee M K, Seo J K, Kim H K, et a1.A vector system for introducing foreign HIV1 env genes and pseudotyping of MuLV particles with the recombinant HIV1 envelope proteins for antiHIV1 assay. Antiviral Res, 2002, 53(2):99111.
［18］ Takeuchi Y, Simpson G, Vile R G,et al. Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by Ctype, but not Dtype, retroviruses. Virology, 1992 , 186(2):792794.
［19］苗文泉,李敬云.抗HIV药物的筛选评价方法. 国外医学药学分册, 2007, 34(3):170173. Miao W Q, Li J Y.Foreign Medical Sciences Section of Pharmacy, 2007, 34(3): 170173.
［20］ Kageyama S, Kurokawa M, Shiraki K. Extract of prunella vulgaris spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo. Antivir Chem Chemother,2000,11(2): 157164.
［21］ Westby M, Nakayama G R, Butler S L, et al. Cellbased and biochemical screening approaches for the discovery of novel HIV1 inhibitors. Antiviral Res, 2005, 67(3): 121140.
［22］ GarciaPerez J, SanchezPalomino S, PerezOlmeda M, et al. A new strategy based on recombinant viroses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.J Med Virol, 2007,79(2):127137.
［23］ Stuyver L,Wyseur A, Rombout A, et a1. Line probe assay for rapid detection of drugselected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother, 1997, 41(2): 284291.
［24］ Erali M, Page S, Reimer LG, et a1. Human immunodeficiency virus type 1 drug resistance testing: A comparison of three sequencebased methods. J Clin Microbiol, 2001, 39(6): 21572165.
［25］ Iga M, Matsuda Z, Okayama A, et a1. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J Virol Methods, 2002, 106(1): 2537.
［26］ Race E, Dam E, Obry V, et a1. Analysis of HIV crossresistance to protease inhibitors using a rapid singlecycle recombinant virus assay for patients failing on combination therapies. AIDS, 1999, 13(15): 20612068.
［27］ PerezElias M J, GarciaArota I, Munoz V, et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antivir Ther, 2003, 8(6): 577584.
［28］ Japour A J, Mayers D L, Johnson V A, et a1. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother, 1993, 37(5):10951101.
［29］ Paolucci S, Baldanti1 F, Zavattoni M, et al. Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV1 variants. J Antimicrob Chemother, 2004, 53(5): 766771.

[1]	安明晖,田文,韩晓旭,尚红. 表达HIV单链抗体的重组乳酸杆菌的构建及表型分析 ^*[J]. 中国生物工程杂志, 2019, 39(10): 1-8.
[2]	王景丽,丁真真,刘辉,唐延婷. 以番茄斑萎病毒核蛋白为靶点的荧光偏振药物筛选体系的建立及应用 ^*[J]. 中国生物工程杂志, 2018, 38(11): 18-24.
[3]	袁雅红, 赵珊珊, 王小莉, 腾智平, 李东升, 曾毅. HIV-1 Tat蛋白抑制骨髓间充质干细胞的造血支持功能[J]. 中国生物工程杂志, 2017, 37(6): 1-8.
[4]	王小莉, 余庆, 袁雅红, 腾智平, 李东升, 曾毅. 打靶恒河猴CD4⁺ T细胞的TRIM5α基因影响其感染HIV的能力[J]. 中国生物工程杂志, 2017, 37(2): 15-19.
[5]	朱云鹏, 王鹏, 夏博然, 唐延婷, 王权. SARS冠状病毒主蛋白酶抑制剂的筛选及抑制动力学研究[J]. 中国生物工程杂志, 2016, 36(4): 35-42.
[6]	朱羿龙, 李昌, 郭焱, 刘存霞, 杜寿文, 王茂鹏, 金宁一. *表达HIV-1 gag重组鸡痘病毒的构建与筛选*[J]. 中国生物工程杂志, 2014, 34(1): 57-63.
[7]	聂伦, 吴文言. RANTES衍生物与HIV-1进入抑制剂[J]. 中国生物工程杂志, 2013, 33(2): 96-102.
[8]	刘斌, 刘昕, 李杉, 何红秋, 张小轶, 谭建军, 陈慰祖, 王存新. HIV-1整合酶链转移反应抑制剂的荧光筛选方法[J]. 中国生物工程杂志, 2013, 33(1): 67-71.
[9]	李建彬, 米志强, 安小平, 谭莉, 陈斌, 王晓娜, 范华昊, 张文慧, 张博, 方祥, 童贻刚. shRNA随机文库结合TK自杀基因筛选靶向HIV-1LTR相关宿主因子[J]. 中国生物工程杂志, 2012, 32(09): 48-54.
[10]	何红秋, 贾渝跃. HIV-1整合酶核心区可溶性表达及抑制剂筛选[J]. 中国生物工程杂志, 2012, 32(03): 14-19.
[11]	何红秋, 刘斌, 陈慰祖, 王存新. 分子信标方法研究HIV-1整合酶3'加工反应动力学[J]. 中国生物工程杂志, 2012, 32(02): 76-81.
[12]	王子晔, 冯娟, 马雪梅, 王明连, 钟儒刚. 利用噬菌体肽库筛选与HIV-1p24抗原结合的多肽[J]. 中国生物工程杂志, 2011, 31(5): 104-107.
[13]	张浩圆, 吴文言. HIV进入抑制剂的研究进展[J]. 中国生物工程杂志, 2011, 31(5): 113-120.
[14]	史文芳, 冯悦, 魏大巧, 夏雪山. 丙型肝炎病毒靶向药物及抗病毒药物筛选[J]. 中国生物工程杂志, 2011, 31(11): 95-101.
[15]	王子晔冯娟马雪梅王明连钟儒刚. 利用噬菌体肽库筛选与HIV-1p24抗原结合的多肽[J]. 中国生物工程杂志, 2011, 31(05): 0-0.

Viewed

Full text

Abstract

Cited

Shared

Discussed